The Flaxil Label (A) Harvard Case Solution & Analysis

This case focuses on the 2001 negotiations between Mytex pharmaceuticals and the U.S. Food and Drug Administration (FDA). Outcome of the negotiations will determine the new label for the blockbuster drug for arthritis Mytex, Flaxil. Negotiations rather qualitative and different from the typical price negotiations with which students are familiar. However, at stake was $ 500 million in sales Flaxil and security of millions of patients. (A) case represents the views and Mytex FDA on new evidence Flaxil can have side effects. "Hide
by Gregory Barron Source: Harvard Business School 10 pages. Publication Date: August 24, 2008. Prod. #: 909001-PDF-ENG

Share This

SALE SALE

Save Up To

30%

IN ONLINE CASE STUDY

FOR FREE CASES AND PROJECTS INCLUDING EXCITING DEALS PLEASE REGISTER YOURSELF !!

Register now and save up to 30%.